Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

NCT05879926 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT05879926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05879926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
October 18, 2023
Completion date
July 31, 2034
Enrollment
3,960 (estimated)
Sites
1,261

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer